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1 These authors contributed equally to this work.Induced pluripotent stem (iPS) cells were recently established from human ﬁbroblasts. In the pres-
ent study we investigated the adipogenic differentiation properties of four human iPS cell lines and
compared them with those of two human embryonic stem (ES) cell lines. After 12 days of embryoid
body formation and an additional 10 days of differentiation on Poly-L-ornithine and ﬁbronectin-
coated dishes with adipogenic differentiation medium, human iPS cells exhibited lipid accumula-
tion and transcription of adipogenesis-related molecules such as C/EBPa, PPARc2, leptin and aP2.
These results demonstrate that human iPS cells have an adipogenic potential comparable to human
ES cells.
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Pluripotent embryonic stem (ES) cells have been considered po-
tent candidates for regenerative medicine as an unlimited source
of cells for the transplantation therapy and a useful tool for the
investigation of cell development/differentiation, especially after
establishment of human ES cells [1]. We previously clariﬁed the
differentiation process of mouse, monkey and human ES cells into
vascular cells [2–4] and demonstrated that transplantation of vas-
cular cells derived from human ES cells may constitute a novel
strategy for vascular regeneration [4,5]. A number of immunologi-
cal and ethical problems remain to be overcome before clinical
application of the ES cells, however. Recently, novel ES cell-like
pluripotent cells, termed induced pluripotent stem (iPS) cells, werechemical Societies. Published by E
(M. Sone), kh@kuhp.kyoto-generated by introducing four transcription factors (Oct3/4, Sox2,
Klf4 and c-Myc) into mouse skin ﬁbroblasts [6], and soon thereaf-
ter iPS cells were also generated from human skin ﬁbroblasts [7,8].
Since then, a new generation of human iPS cells has been generated
by introducing into ﬁbroblasts just three of the aforementioned
transcription factors (c-Myc was omitted) [9]. By overcoming the
immunological and ethical problems associated with ES cells, iPS
cells open a new avenue for cell transplantation-based regenera-
tive medicine and provide a powerful new tool with which to
investigate organ development/differentiation in speciﬁc disease
states, especially in inherited diseases.
Generalized lipodystrophy consists of congenital and acquired
types characterized by the lack of the whole adipose tissue, which
leads to severe insulin-resistant diabetes, hypertriglyceridemia
and fatty liver. We previously analyzed genes and phenotypes of
congenital generalized lipodystrophic Japanese [10] and also dem-
onstrated the long-lasting efﬁcacy and safety of the leptin-replace-
ment therapy in these patients [11–13]. Since metabolic
abnormality in the mouse model is known to be cured by maturelsevier B.V. All rights reserved.
Table 1
Primers for reverse-transcription polymerase chain reaction.
Gene Sequence
Nanog Sense CAGCCCCGATTCTTCCACCAGTCCC
Antisense CGGAAGATTCCCAGTCGGGTTCACC
PPARc2 Sense ATTGACCCAGAAAGCGATTC
Antisense CAAAGGAGTGGGAGTGGTCT
C/EBPa Sense GCAAACTCACCGCTCCAATG
Antisense TTAGGTTCCAAGCCCCAAGTC
aP2 Sense AACCTTAGATGGGGGTGTCCTG
Antisense TCGTGGAAGTGACGCCTTTC
Leptin Sense GAACCCTGTGCGGATTCTTGTG
Antisense CGTTTCTFFAAGGCATACTGGTGAG
GAPDH Sense ACCACAGTCCATGCCATCAC
Antisense TCCACCACCCTGTTGCTGT
PPARc2 (real-time RT-PCR) Sense GATACACTGTCTGCAAACATATCACAA
Antisense CCACGGAGCTGATCCCAA
Probe AGAGATGCCATTCTGGCCCACCAACTT
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pose tissue with human iPS cells-derived adipocytes is the ideal
goal for lipodystrophic patients. Moreover, in vitro adipogenic dif-
ferentiation system of human iPS cells will contribute to elucidate
the pathogenesis of congenital generalized lipodystrophy when iPS
cell lines are established from patients with lipodystrophy. In the
present study we have investigated the adipogenic differentiation
of human iPS cells and compared with that of human ES cells.
2. Materials and methods
2.1. Cells and culture
Four human iPS cell lines (201B6, 201B7, 253G1 and 253G4)
were investigated. The 201B6 (B6) and 201B7 (B7) lines were gen-
erated by introducing four transcription factors (Oct3/4, Sox2, Klf4
and c-Myc) into human skin ﬁbroblasts while the 253G1 (G1) and
253G4 (G4) lines were generated using only three factors (c-Myc
was omitted) [9]. These iPS cell lines were maintained as previ-
ously described [7]. Two human ES cell lines (H9 and KhES-1) were
used and maintained as previously described [1,14].
2.2. Adipogenic differentiation
For embryoid body (EB) formation, iPS and ES colonies were di-
gested with 1 mg/ml collagenase type IV (GIBCO, CA, USA) and pla-
ted onto non-adherent bacterial culture dishes, where they were
allowed to aggregate in maintenance medium without bFGF. Reti-
noic acid (Sigma–Aldrich, Japan) was added to the medium to a
concentration of 100 nM from day 2 to day 5. After 12 days, EBs
were transferred to 6-well plates coated with a combination of
30 lg/ml Poly-L-ornithine (Sigma–Aldrich) and 2 lg/ml ﬁbronectin
(Sigma–Aldrich). To induce adipocyte differentiation from iPS and
ES cells, we applied a modiﬁcation of a procedure described previ-
ously for use with mouse and human ES cells (Fig. 1) [15–19]. Dif-
ferentiation was induced for 10 days using medium consisting of
DMEM-F12, 10% KSR, and an adipogenic cocktail (0.5 mM IBMX,
0.25 lM dexamethasone, 1 lg/ml insulin, 0.2 mM indomethacin
and 1 lM pioglitazone).
2.3. Immunocytochemistry
Immunocytochemistry was carried out as previously described
[7]. The anti-human primary antibodies included Nanog (R&D Sys-
tems, MN, USA) and Alexa 488-conjugated SSEA-4 (Santa Cruz Bio-
technology Inc., CA, USA) and TRA1-60 (CHEMICON, LA, USA). The
TRA1-60 antibody was labeled using an Alexa Fluor 488 Monoclo-
nal Antibody Labeling Kit (Molecular Probes, OR, USA). Alexa 546-
conjugated donkey anti-sheep IgG (Molecular Probes, OR, USA)
served as the secondary antibody. Alkaline phosphatase activity
was detected using a BCIP/NBT substrate system (Dakocytomation,
CA, USA).
2.4. Oil Red O staining and microscopic analysis of adipocytes
Cells were washed with phosphate-buffered saline (PBS) twice,
ﬁxed in 3.7% formaldehyde for 1 h and then stained with 0.6% (w/v)
Oil Red O (Nacalai Tesque, Japan) solution (60% isopropanol, 40%Day0 2 5 1RA
100nM
EB formation with 20% KSR
Fig. 1. Schematic diagram of the experimental protocol used for adipocyte differentiat
0.5 mM IBMX, 0.25 lM dexamethasone, 1 lg/ml insulin, 0.2 mM indomethacin and 1 lMwater) for 2 h at room temperature. The cells were then washed
with water to remove unbound dye. Subsequently, the bound Oil
Red O was eluted with isopropanol.
After staining with Oil Red O, each EB was examined microscop-
ically for the presence of adipocyte colonies, and the percentage of
EBs with outgrowths showing adipocyte positivity was determined
as previously described [15]. EBs in which adipocytes accounted
for more than half of their circumference were considered adipo-
cyte-positive. The percent area of Oil Red O staining (+) was deter-
mined at 20 magniﬁcation by counting the number of pixels
exhibiting Oil Red O positivity in selected microscope ﬁelds
(449  338 pixels). Four randomly selected ﬁelds were examined
in each well of a 6-well plate, and the percent area was calculated
as the average for the four ﬁelds. Six independent experiments
were performed for each cell line.
2.5. Reverse-transcription polymerase chain reaction (RT-PCR) and
quantitative real-time PCR
Total RNA was extracted using TRizol Reagent (Invitrogen, CA,
USA) and treated with RNase-Free DNase Set (QIAGEN, Germany)
to remove any contaminating genomic DNA. For RT-PCR, cDNA was
synthesized using a PrimeScript RT reagent Kit (Takara Bio Inc., Ja-
pan), after which RT-PCR was run using ExTaq (Takara Bio Inc.). For
quantitative real-timePCR, TaqManPCRwas carriedout using a Step
One Plus Real-Time PCR System as instructed by the manufacturer
(Applied Biosystems, CA, USA). Levels of mRNA were normalized to
those of 18S mRNA. The primers used are listed in Table 1.
2.6. Statistical analysis
Data are expressed as means ± S.E.M. Statistical signiﬁcance
was evaluated using ANOVA for comparison among six groups.
Values of P < 0.05 were considered signiﬁcant.
3. Results
3.1. Adipogenic differentiation of human iPS and ES cells
Morphological phenotypes, immunoreactivities of Nanog, SSEA-
4 and TRA-1-60, and ALP activity of human iPS cells did not differ2 22
attached on coated dish with adipogenic cocktail
ion from human ES and human iPS cells. EB: embryoid body. Adipogenic cocktail:
pioglitazone.
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tial for adipogenic differentiation, the human iPS cells were sub-
jected to adipogenic induction culture. After 12 days of EB
formation, EBs derived from human iPS cells were attached to
coated dishes to induce differentiation. Several kinds of coating
for the dishes, including gelatin, collagen IV and ﬁbronectin were
compared, and the efﬁciency of EB attachment and adipogenic dif-
ferentiation were the best on dishes coated with a combination of
Poly-L-ornithine and ﬁbronectin. On day 15, after 3 days of adipo-
genic differentiation following the EB formation, differentiated
cells containing small cytoplasmic lipid droplets were observed
spreading outward from the attached EBs. On day 22, the lipid
accumulation was evaluated by staining the cells with Oil Red O.
To evaluate the adipogenic potential of individual iPS cell lines,
the percentage of EB outgrowths having adipocyte colonies and the
percent area of Oil Red O staining (+) were determined. For each of
iPS and ES cell lines tested, 40–60% of EBs formed adipocyte colo-
nies (Table 2). In all of the iPS cell lines, lipid accumulation was
similar to that seen in human ES cell lines (Fig. 3), though the B7
line showed stronger lipid accumulation than the other cell lines.Fig. 2. Morphology of undifferentiated human iPS cells (G4). (A) Phase-contrast
photomicrograph of an undifferentiated colony. (B) Alkaline phosphatase activity.
(C) Immunoﬂuorescent staining with Nanog. (D) Immunoﬂuorescent staining with
SSEA-4. (E) Immunoﬂuorescent staining with TRA1-60. Scale bar = 100 lM.
Table 2
% of EBs with adipocyte colonies.
Cell line [Number of EBs with adipocytecolonies/total number of EBs]
201B6 54.1% [40/74]
201B7 59.7% [46/77]
253G1 50.0% [35/70]
253G4 56.4% [44/78]
H9 48.8% [39/80]
KhES-1 45.5% [35/77]
Fig. 3. Oil Red O staining of adipocytes derived from human iPS cells (A–D) and ES
cells (E, F) on day 22. B6 (B) B7 (C) G1 (D) G4 (E) H9 (F) KhES-1. Scale bar = 50 lM.Statistical analysis of the percent area of Oil Red O staining (+)
showed no signiﬁcant differences among the cell lines (Fig. 4).3.2. Expression of adipogenesis-related molecules
Using RT-PCR, transcription of adipogenic markers was investi-
gated on days 0 and 22 of differentiation (Fig. 5A). Though not de-
tected at day 0, mRNAs encoding the adipogenic transcription
factors C/EBPa (CCAAT/enhancer binding protein a) and PPARc2
(peroxisome proliferator-activated receptor c2) were detected on
day 22. In contrast, expression of Nanog mRNA was strongly sup-
pressed on day 22, as compared with its expression on day 0.
Expression of the mature adipocyte markers leptin and aP2 (adipo-
cyte fatty acid binding protein) was also clearly detected on day 22.
All of the human iPS cell lines expressed mRNAs encoding adipo-
genesis-related molecules at levels that were comparable to the
levels seen in human ES cell lines (Fig. 5A). In Quantitative real-
time PCR analysis, expression of PPARc2 mRNA differed somewhat
among the iPS and ES cell lines. The differences between the B7
line and the two ES cell lines were signiﬁcant, but other differences
were not signiﬁcant (Fig. 5B).pe
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Fig. 4. Percent area of Oil Red O staining. Results are means of six independent
experiments. No signiﬁcant differences were observed among the iPS and ES cell
lines.
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Fig. 5. (A) Transcription of the adipocyte-speciﬁc markers PPARc2, CEBP/a, aP2 and
leptin. RNA samples from undifferentiated human iPS cells (B7, day 0) and
differentiated stage iPS cells (B6, B7, G1, G4) and human ES cells (H9, KhES-1), as
well as mature human adipocytes differentiated from human adipose-derived
mesenchymal stem cells (positive control), were analyzed by RT-PCR. Nanog is an
undifferentiated human ES cell marker. GAPDH served as an internal standard for
RT-PCR. Kh1: KhES-1. Adipose: human mature adipocytes differentiated from
human adipose-derived mesenchymal stem cells. (B) Relative levels of PPARc2
mRNA expression are shown as means ± S.E.M. of 4–6 independent experiments
and normalized to those of 18S. The levels are expressed as percentages of the
expression in the H9 cell line. *P < 0.05 vs. H9. **P < 0.05 vs. KhES-1.
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The present study demonstrates that human iPS cells have adi-
pogenic potential comparable to human ES cells. Four human iPS
cell lines of two generations were investigated. The B6 and B7 were
generated by introducing four transcription factors (Oct3/4, Sox2,
Klf4 and c-Myc) into human skin ﬁbroblasts while the G1 and G4
were generated using only three factors (c-Myc was omitted) [9].
After 12 days of embryoid body formation and an additional
10 days of differentiation on Poly-L-ornithine and ﬁbronectin-
coated dishes with adipogenic differentiation medium, all human
iPS cell lines of both generations exhibited lipid accumulation
and transcription of such adipogenesis-related molecules as C/
EBPa, PPARc2, leptin and aP2. We also compared differentiation
efﬁciency between human iPS and ES cells using two lines of hu-
man ES cells and found no apparent difference between human
iPS and ES cells in properties of adipogenic differentiation includ-
ing the time course and potential. In terms of lipid accumulation
and transcription of adipogenesis-related molecules, human iPS-
derived adipocytes appear to reach at least the same level of matu-
rity as those derived from human ES cells. The B7 line tended to
show stronger adipogenic potential than the other ﬁve iPS lines
and the ES cell lines, but the difference in terms of percent area
of Oil Red O staining (+) was not signiﬁcant. The B7 line also
showed signiﬁcantly stronger expression of PPARc2 than the two
ES cell lines tested, but PPARc2 expression varied among the dif-
ferent iPS cell lines, despite their having the same genetic back-
ground. We conclude that the adipogenic potential of iPS cells
did not essentially differ from ES cells, though their adipogenic
potentials were rather varied in each line.Despite the prevalence of obesity, systems for research into hu-
man adipocyte biology remain underdeveloped, in part because of a
lack of available human adipocyte cell lines. There are signiﬁcant
differences between adipocyte development in humans and mice
[20]. The established in vitro adipocyte differentiation system using
human iPS cells in the present study should make it possible to dis-
sect out the cellular mechanisms underlying human adipocyte dif-
ferentiation. It should also contribute to the better understanding of
adipocyte biology and serve as a basis for advances in research into
obesity and adipotoxicity, which has been proposed as the sum of
the negative effects associated with obesity [21].
Adipogenesis is largely divided into two phases: the early
phase consisting of the lineage commitment of adipocytes from
pluripotent stem cells and the late phase consisting of the termi-
nal differentiation of preadipocytes into adipocytes [22]. The
molecular mechanism underlying the terminal adipocyte differen-
tiation has been identiﬁed through analysis of the differentiation
process in immortalized mouse preadipocyte cell lines (e.g., 3T3-
L1 and 3T3-F442A cells) [22–24], but the differentiation from plu-
ripotent stem cells during the early stage of adipogenesis must
await further clariﬁcation. The establishment of adipocyte differ-
entiation system with human iPS cells should facilitate that line
of research.
In contrast to human ES cells, iPS cells can be induced from any
human being irrespective of their genetic make-up. Consequently,
the study of iPS cells should contribute to the identiﬁcation of new
susceptibility genes associated with obesity and metabolic syn-
drome, and to the clariﬁcation of the functions of those genes.
The establishment of iPS cell lines from patients with inherited dis-
eases presenting adipocyte abnormality should enable clariﬁcation
of their pathogenesis. And because they overcome the immunolog-
ical and ethical problems associated with human ES cells, iPS cell
systems should also contribute to the development of novel regen-
erative therapies for reconstruction of soft tissue defects after tu-
mor resections, extensive deep burns and lipodystrophy. The
induced cells obtained with our protocol are not a homogeneous
population. Consequently, at this stage human iPS cells may not
yet have as much adipogenic potential as adipose-derived stem
cells (ADSCs), which are derived from the stromal vascular fraction
of human adipose tissue and are thought to be a safe and useful
tool in adipose regenerative medicine [25]. About 80% of ADSCs dif-
ferentiate into adipocytes under suitable conditions [26]. The next
issue we plan to address will be the establishment of an improved
differentiation protocol that includes a puriﬁcation process such as
cell sorting.
In conclusion, the present study demonstrates that human iPS
cells have adipogenic potential that is generally equal to that of hu-
man ES cells. The use of iPS cells will contribute to the development
of regenerative therapies of adipose tissue for lipodystrophy. This
work should also contribute to our understanding of human adipo-
genesis and to the clariﬁcation of the pathogenesis and pathophys-
iology of obesity and metabolic syndrome, potentially leading to
the development of new drug therapies.
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